Details for New Drug Application (NDA): 210604
✉ Email this page to a colleague
NDA 210604 describes CAPECITABINE, which is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms, Dr Reddys, Eugia Pharma, Hetero Labs Ltd V, Hikma, MSN, Reliance Life, Rising, Shilpa, Sun Pharm, Teva Pharms Usa, and Teyro Labs, and is included in fourteen NDAs. It is available from twenty-one suppliers. Additional details are available on the CAPECITABINE profile page.
The generic ingredient in CAPECITABINE is capecitabine. There are twenty-eight drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the capecitabine profile page.
The generic ingredient in CAPECITABINE is capecitabine. There are twenty-eight drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the capecitabine profile page.
Summary for 210604
| Tradename: | CAPECITABINE |
| Applicant: | Eugia Pharma |
| Ingredient: | capecitabine |
| Patents: | 0 |
Pharmacology for NDA: 210604
| Mechanism of Action | Nucleic Acid Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for 210604
Suppliers and Packaging for NDA: 210604
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CAPECITABINE | capecitabine | TABLET;ORAL | 210604 | ANDA | Aurobindo Pharma Limited | 59651-204 | 59651-204-10 | 1 BLISTER PACK in 1 CARTON (59651-204-10) / 10 TABLET in 1 BLISTER PACK |
| CAPECITABINE | capecitabine | TABLET;ORAL | 210604 | ANDA | Aurobindo Pharma Limited | 59651-204 | 59651-204-60 | 60 TABLET in 1 BOTTLE (59651-204-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
| Approval Date: | Apr 17, 2018 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
| Approval Date: | Apr 17, 2018 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
